AI Article Synopsis
Article Abstract
Background: Familial hypercholesterolemia (FH) affects more than one million Americans, and most individuals have not been formally diagnosed with the condition. Individuals with FH have markedly elevated serum low-density lipoprotein cholesterol (LDL-C) levels from birth that substantially increase their risk for early-onset cardiovascular (CV) events. Guideline-recommended treatments exist to lower LDL-C and reduce the risk of CV events in individuals with FH and hypercholesterolemia. This study seeks to address a significant gap in the care of individuals with FH by systematically developing an effective approach to increase the adoption of guideline-recommended treatments for FH.
Methods: This developmental study will consist of three aims: 1) determine the barriers to and facilitators of treatment of FH; 2) develop a list of potential implementation strategies to promote the adoption of guideline-recommended treatment of individuals with FH, and 3) pilot one implementation strategy from Aim 2 in one health care system to evaluate implementation outcomes of the strategy. The Practical, Robust Implementation and Sustainability Model will guide this project, including the development of interview questions, implementation strategies, and evaluation of the implementation strategy. The implementation outcomes include: of individuals targeted by the implementation strategy, how many are impacted by it (reach), measure the change in knowledge, attitude, and behavior that is impacted by the implementation strategy (effectiveness), in settings targeted by the implementation strategy, how many adopt it (adoption), and fidelity and cost of the implementation strategy (implementation). Data sources will include electronic health records, administrative databases, surveys, and semi-structured interviews.
Discussion: The inclusion of patient and organizational stakeholder experiences is a critically important step in developing efficient and effective implementation strategies. Additionally, perspectives from a variety of geographic areas and cultural perspectives should increase feasibility and fidelity of the interventional approach to improve adoption of guideline-recommended practices for FH care.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911646 | PMC |
| http://dx.doi.org/10.1016/j.sapharm.2019.06.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the scalability of health system interventions in Africa: protocol for a Delphi study.
Health Res Policy Syst
December 2024
Health Information System, World Health Organization (WHO) Regional Office for Africa, Brazzaville, Republic of Congo.
Background: There is widespread enthusiasm for scaling interventions to strengthen health systems. However, little is known about the scalability of such interventions in Africa. In this study, we seek to assess the scalability of interventions for improving the functionality of health systems in Africa, as a key to large-scale implementation strategy of interventions with potential for impact.
View Article and Find Full Text PDFPrecision autofocus in optical microscopy with liquid lenses controlled by deep reinforcement learning.
Microsyst Nanoeng
December 2024
School of Mechanical and Electrical Engineering, Soochow University, No.8 Jixue Road, Suzhou City, Jiangsu, 215000, China.
Microscopic imaging is a critical tool in scientific research, biomedical studies, and engineering applications, with an urgent need for system miniaturization and rapid, precision autofocus techniques. However, traditional microscopes and autofocus methods face hardware limitations and slow software speeds in achieving this goal. In response, this paper proposes the implementation of an adaptive Liquid Lens Microscope System utilizing Deep Reinforcement Learning-based Autofocus (DRLAF).
View Article and Find Full Text PDFMechanical Circulatory Support for Massive Pulmonary Embolism.
J Am Heart Assoc
December 2024
Department of Health Abu Dhabi UAE.
Up to 50% of patients with pulmonary embolism (PE) experience hemodynamic instability and approximately 70% of patients who die of PE experience an accelerated cascade of symptoms within the first hours of onset of symptoms, thus necessitating rapid evaluation and intervention. Venoarterial extracorporeal membrane oxygenation and other ventricular assist devices, depending on the hemodynamic derangements present, may be used to stabilize patients with massive PE refractory to initial therapies or with contraindications to other interventions. Given the abnormalities in both pulmonary circulation and gas exchange caused by massive PE, venoarterial extracorporeal membrane oxygenation may be considered the preferred form of mechanical circulatory support for most patients.
View Article and Find Full Text PDFThrombosis, Translational Medicine, and Biomarker Research: Moving the Needle.
J Am Heart Assoc
December 2024
Cardiovascular Research Institute Maastricht, Maastricht University Maastricht Netherlands.
Arterial and venous thromboembolism are leading causes of morbidity and death worldwide. Despite significant advances in the diagnosis, prognostication, and treatment of thrombotic diseases over the past 3 decades, the adoption of findings stemming from translational biomarker research in clinical practice remains limited. Biomarkers provide an opportunity to enhance our understanding of pathophysiological processes and optimize treatment strategies.
View Article and Find Full Text PDFCluster randomised controlled trial of double-dose azithromycin mass drug administration, facial cleanliness and fly control measures for trachoma control in Oromia, Ethiopia: the stronger SAFE trial protocol.
BMJ Open
December 2024
Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Introduction: Trachoma is caused by the bacterium (). The WHO recommends the SAFE strategy for trachoma elimination: Surgery for trichiasis, Antibiotics, Facial cleanliness and Environmental improvement. Multiple rounds of SAFE implementation have proven insufficient to eliminate trachoma in Ethiopia, where over 50% of the global trachoma burden remains.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!